观察恩替卡韦与乙肝疫苗联合治疗慢性乙肝的临床效果与应用可行性

To Observe the Clinical Effect and Application of Entecavir Combined with Hepatitis B Vaccine in the Treatment of Chronic Hepatitis Bfeasibility

目的分析恩替卡韦与乙肝疫苗联合治疗慢性乙肝的临床效果与应用可行性。方法选择2018年2月至2019年2月我院收治80例慢性乙肝患者,采用随机表法将所有患者分成观察组与对照组,每组40例。对照组采用恩替卡韦治疗,观察组采用恩替卡韦联合乙肝疫苗治疗,对比两组治疗效果。结果观察组的HBeAg血清转换率为70.00%高于对照组的42.50%,差异具有统计学意义(P<0.05);观察组的HBV-DNA降低率为82.50%,优于对照组的55.00%,差异具有统计学意义(P<0.05)。观察组的各纤维化指标都低于对照组,差异具有统计学意义(P<0.05)。观察组的表面抗原滴度低于对照组,差异具有统计学意义(P<0.05)。观察组的表面抗体滴度高于对照组,差异具有统计学意义(P<0.05)。结论在治疗慢性乙肝患者时,应用恩替卡韦联合乙肝疫苗治疗,治疗效果突出,可以有效转变相关指标,提高患者血清转换率,推动患者尽早恢复健康,应用价值高。

Objective To analyze the clinical effect and feasibility of entecavir combined with hepatitis B vaccine in the treatment of chronic hepatitis B.Methods From February 2018 to February 2019,80 patients with chronic hepatitis B were treated in our hospital.All patients were divided into observation group and control group with 40 cases in each group by random table method.The control group was treated with entecavir,while the observation group was treated with entecavir combined with hepatitis B vaccine.Results The serum conversion rate of HBAg in the observation group was 70.00%higher than that in the control group(42.50%,P<0.05).The decrease rate of HBV-DNA in the observation group was 82.50%,which was better than that in the control group(55.00%,P<0.05).The fibrosis indexes of the observation group were lower than those of the control group,and the difference was statistically significant(P<0.05).The titer of surface antigen in the observation group was lower than that in the control group(P<0.05).The titer of surface antibody in the observation group was higher than that in the control group(P<0.05).Conclusion Entecavir combined with hepatitis B vaccine is effective in treating chronic hepatitis B patients.It can effectively change the relevant indicators,improve the serum conversion rate,and promote the recovery of patients as soon as possible.